Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Gleave, ME' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 59 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Zellweger, T; Miyake, H; July, LV; Akbari, M; Kiyama, S; Gleave, ME
      Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin

      NEOPLASIA
    2. Miyake, H; Hara, S; Zellweger, T; Kamidono, S; Gleave, ME; Hara, I
      Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells

      MOLECULAR UROLOGY
    3. Miyake, H; Hara, I; Kamidon, S; Gleave, ME
      Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity

      INTERNATIONAL JOURNAL OF UROLOGY
    4. Hara, I; Miyake, H; Gleave, ME; Kamidono, S
      Introduction of Clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo

      JAPANESE JOURNAL OF CANCER RESEARCH
    5. Trachtenberg, J; Newling, DWW; Gleave, ME; Lubeck, DP; Kirschenbaum, A; Sylvester, J
      Discussion following Dr. Geert J.C.M. Kolvenbag's presentation

      UROLOGY
    6. Daniell, HW; Chen, S; Fair, WR; Heston, WDW; Pirani, JF; Bubley, GJ; Carroll, PR; Gleave, ME
      Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations

      UROLOGY
    7. Gleave, ME; Miyake, H; Zellweger, T; Chi, K; July, L; Nelson, C; Rennie, P
      Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

      UROLOGY
    8. Lieberman, R; Gleave, ME; Carroll, PR; Bubley, GJ
      Discussion following Dr. Martin E. Gleave's presentation

      UROLOGY
    9. Carroll, PR; D'Amico, A; Malkowicz, SB; Gleave, ME; Bubley, GJ
      Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion

      UROLOGY
    10. Fair, WR; Newling, DWW; Heston, WDW; Trachtenberg, J; Malkowicz, SB; Gleave, ME
      The role of diethylstilbestrol in the treatment of prostate cancer - Discussion

      UROLOGY
    11. Gleave, ME; Goldenberg, SL; Chin, JL; Warner, J; Saad, F; Klotz, LH; Jewett, M; Kassabian, V; Chetner, M; Dupont, C; Van Rensselaer, S
      Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects

      JOURNAL OF UROLOGY
    12. Zellweger, T; Miyake, H; Cooper, S; Chi, K; Conklin, BS; Monia, BP; Gleave, ME
      Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2 '-O-(2-methoxy)ethyl chemistry

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    13. Leung, S; Miyake, H; Zellweger, T; Tolcher, A; Gleave, ME
      Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

      INTERNATIONAL JOURNAL OF CANCER
    14. Gleave, ME; Miyake, H; Nelson, C; Rennie, P; Leung, S
      Targeting antiapoptotic genes upregulated by androgen withdrawal using antisense oligodeoxynucleotides to enhance androgen-and chemo-sensitivity in prostate cancer

      PROSTATE CANCER
    15. Gleave, ME; La Bianca, S; Goldenberg, SL
      Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls

      PROSTATE CANCER AND PROSTATIC DISEASES
    16. Bruchovsky, N; Klotz, LH; Sadar, M; Crook, JM; Hoffart, D; Godwin, L; Warkentin, M; Gleave, ME; Goldenberg, SL
      Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations

      MOLECULAR UROLOGY
    17. Miyake, H; Chi, KN; Gleave, ME
      Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo

      CLINICAL CANCER RESEARCH
    18. Ting, A; Gleave, ME; Hsiang, YN
      Regarding "In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cava" - Reply

      JOURNAL OF VASCULAR SURGERY
    19. Leung, SYL; Jackson, J; Miyake, H; Burt, H; Gleave, ME
      Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors

      PROSTATE
    20. Gleave, ME; La Bianca, SE; Goldenberg, SL; Jones, EC; Bruchovsky, N; Sullivan, LD
      Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up

      UROLOGY
    21. Miyake, H; Monia, BP; Gleave, ME
      Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense bcl-xL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

      INTERNATIONAL JOURNAL OF CANCER
    22. Miyake, H; Nelson, C; Rennie, PS; Gleave, ME
      Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3 '-kinase pathway

      ENDOCRINOLOGY
    23. Miyake, H; Nelson, C; Rennie, PS; Gleave, ME
      Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models

      CANCER RESEARCH
    24. Sadar, MD; Gleave, ME
      Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells

      CANCER RESEARCH
    25. Jackson, JK; Gleave, ME; Yago, V; Beraldi, E; Hunter, WL; Burt, HM
      The suppression of human prostate tumor growth in mice by the injection ofa slow-release polymeric paste formulation of paclitaxel

      CANCER RESEARCH
    26. Miyake, H; Pollak, M; Gleave, ME
      Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models

      CANCER RESEARCH
    27. Miyake, H; Nelson, C; Rennie, PS; Gleave, ME
      Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer

      CANCER RESEARCH
    28. Miayake, H; Tolcher, A; Gleave, ME
      Chemosensitization and delayed androgen-independent recurrence of prostatecancer with the use of antisense Bcl-2 oligodeoxynucleotides

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    29. Paterson, RF; Gleave, ME; Jones, EC; Zubovits, JT; Goldenberg, SL; Sullivan, LD
      Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy

      MOLECULAR UROLOGY
    30. Goldenberg, SL; Gleave, ME; Taylor, D; Bruchovsky, N
      Clinical experience with intermittent androgen suppression in prostate cancer: Minimum of 3 years' follow-up

      MOLECULAR UROLOGY
    31. Gleave, ME; Bruchovsky, N; Moore, MJ; Venner, P
      Prostate cancer: 9. Treatment of advanced disease

      CANADIAN MEDICAL ASSOCIATION JOURNAL
    32. Ting, ACW; Gleave, ME; Hsiang, YNH
      In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cava

      JOURNAL OF VASCULAR SURGERY
    33. Gleave, ME; Miayake, H; Goldie, J; Nelson, C; Tolcher, A
      Targeting bcl-2 gene to delay androgen-independent progression and enhancechemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides

      UROLOGY
    34. Miyake, H; Tolcher, A; Gleave, ME
      Antisense BcI-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model

      CANCER RESEARCH
    35. Nickerson, T; Miyake, H; Gleave, ME; Pollak, M
      Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins

      CANCER RESEARCH
    36. Gleave, ME; Goldenberg, SL; Jones, EC; Bruchovsky, N; Sullivan, LD
      Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Analysis of outcome by preoperative risk factors

      MOLECULAR UROLOGY
    37. Roach, M; Pienta, KJ; Gleave, ME; Trachtenberg, J
      Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Analysis of outcome by preoperative risk factors - Discussion

      MOLECULAR UROLOGY
    38. GLEAVE ME; SATO N; SADAR M; YAGO V; BRUCHOVSKY N; SULLIVAN L
      BUTYRATE ANALOG, ISOBUTYRAMIDE, INHIBITS TUMOR-GROWTH AND TIME TO ANDROGEN-INDEPENDENT PROGRESSION IN THE HUMAN PROSTATE LNCAP TUMOR-MODEL

      Journal of cellular biochemistry
    39. CHOW VDW; SULLIVAN LD; WRIGHT JE; GOLDENBERG SL; FENSTER HN; GLEAVE ME; MCLOUGHLIN MG
      TRANSURETHRAL ELECTROVAPORIZATION OF THE PROSTATE VERSUS TRANSURETHRAL PROSTATIC RESECTION - A COMPARISON OF POSTOPERATIVE HEMORRHAGE

      Urology
    40. GLEAVE ME
      EDITORIAL COMMENT

      Urology
    41. GLEAVE ME; ELHILALI M; FRADET Y; DAVIS I; VENNER P; SAAD F; KLOTZ LH; MOORE MJ; PATON V; BAJAMONDE A
      INTERFERON GAMMA-1B COMPARED WITH PLACEBO IN METASTATIC RENAL-CELL CARCINOMA

      The New England journal of medicine
    42. BRUCHOVSKY N; KLOTZ LH; CROOK JM; ARMITAGE GR; GLEAVE ME; GOLDENBERG SL
      A PHASE-II STUDY OF INTERMITTENT ANDROGEN SUPPRESSION (IAS) IN MEN WITH A RISING SERUM PSA AFTER RADIATION FOR LOCALIZED PROSTATE-CANCER

      The Journal of urology
    43. RABBANI F; GOLDENBERG SL; GLEAVE ME; PATERSON RF; MURRAY N; SULLIVAN LD
      RETROPERITONEAL LYMPHADENECTOMY FOR POSTCHEMOTHERAPY RESIDUAL MASSES - IS A MODIFIED DISSECTION AND RESECTION OF RESIDUAL MASSES SUFFICIENT

      British Journal of Urology
    44. GOLDENBERG SL; GLEAVE ME; BRUCHOVSKY N; RENNIE P
      EDITORIAL COMMENT

      The Journal of urology
    45. GLEAVE ME; SATO N; GOLDENBERG SL; STOTHERS L; BRUCHOVSKY N; SULLIVAN LD
      NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY DECREASES LOCAL RECURRENCE RATES FOLLOWING TUMOR-EXCISION IN THE SHIONOGI TUMOR-MODEL

      The Journal of urology
    46. SATO N; SADAR MD; BRUCHOVSKY N; SAATCIOGLU F; RENNIE PS; SATO S; LANGE PH; GLEAVE ME
      ANDROGENIC INDUCTION OF PROSTATE-SPECIFIC ANTIGEN GENE IS REPRESSED BY PROTEIN-PROTEIN INTERACTION BETWEEN THE ANDROGEN RECEPTOR AND AP-1 C-JUN IN THE HUMAN PROSTATE-CANCER CELL-LINE LNCAP/

      The Journal of biological chemistry
    47. SATO N; GLEAVE ME; BRUCHOVSKY N; RENNIE PS; BERALDI E; SULLIVAN LD
      A METASTATIC AND ANDROGEN-SENSITIVE HUMAN PROSTATE-CANCER MODEL USINGINTRAPROSTATIC INOCULATION OF LNCAP CELLS IN SCID MICE

      Cancer research
    48. SULLIVAN LD; MCLOUGHLIN MG; GOLDENBERG LG; GLEAVE ME; MARICH KW
      EARLY EXPERIENCE WITH HIGH-INTENSITY FOCUSED ULTRASOUND FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY

      British Journal of Urology
    49. SATO N; GLEAVE ME; BRUCHOVSKY N; RENNIE PS; GOLDENBERG SL; LANGE PH; SULLIVAN LD
      INTERMITTENT ANDROGEN SUPPRESSION DELAYS PROGRESSION TO ANDROGEN-INDEPENDENT REGULATION OF PROSTATE-SPECIFIC - ANTIGEN GENE IN THE LNCAP PROSTATE TUMOR-MODEL

      Journal of steroid biochemistry and molecular biology
    50. GOLDENBERG SL; BRUCHOVSKY N; GLEAVE ME; SULLIVAN LD
      LOW-DOSE CYPROTERONE-ACETATE PLUS MINI-DOSE DIETHYLSTILBESTROL - A PROTOCOL FOR REVERSIBLE MEDICAL CASTRATION

      Urology
    51. GLEAVE ME; COUPLAND D; DRACHENBERG D; COHEN L; KWONG S; GOLDENBERG SL; SULLIVAN LD
      ABILITY OF SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS TO PREDICT NORMAL BONE SCANS IN PATIENTS WITH NEWLY-DIAGNOSED PROSTATE-CANCER

      Urology
    52. GOLDENBERG SL; KLOTZ LH; SRIGLEY J; JEWETT MAS; MADOR D; FRADET Y; BARKIN J; CHIN J; PAQUIN JM; BULLOCK MJ; SULLIVAN LD; GLEAVE ME; MCLOUGHLIN MG; PRESTAGE K; KINAHAN TJ; OROVAN WL; WHELAN JP; HERSCHORN S; KERESTECI AG; ROBINETTE M; BRUCE A; STEWART DA; RUETHER JD; ERNST DS; CHETNER M; METCALFE JB; ELHILALI M; APRIKIAN AG; BERTRAND PE; SCHICK E; TESSIER J; HALSALL AK; WECKWORTH PF
      RANDOMIZED, PROSPECTIVE, CONTROLLED-STUDY COMPARING RADICAL PROSTATECTOMY ALONE AND NEOADJUVANT ANDROGEN WITHDRAWAL IN THE TREATMENT OF LOCALIZED PROSTATE-CANCER

      The Journal of urology
    53. GLEAVE ME; GOLDENBERG SL; JONES EC; BRUCHOVSKY N; SULLIVAN LD
      BIOCHEMICAL AND PATHOLOGICAL EFFECTS OF 8 MONTHS OF NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY BEFORE RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY CONFINED PROSTATE-CANCER

      The Journal of urology
    54. RABBANI F; GLEAVE ME; COPPIN CM; MURRAY N; SULLIVAN LD
      TERATOMA IN PRIMARY TESTIS TUMOR REDUCES COMPLETE RESPONSE RATES IN THE RETROPERITONEUM AFTER PRIMARY CHEMOTHERAPY - THE CASE FOR PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION OF STAGE IIB GERM-CELL TUMORS WITH TERATOMATOUS ELEMENTS

      Cancer
    55. GLEAVE ME; CHUNG LWK
      STROMAL EPITHELIAL INTERACTION AFFECTING PROSTATE TUMOR-GROWTH AND HORMONAL RESPONSIVENESS

      Endocrine-related cancer
    56. GOLDENBERG SL; BRUCHOVSKY N; GLEAVE ME; SULLIVAN LD; AKAKURA K
      INTERMITTENT ANDROGEN SUPPRESSION IN THE TREATMENT OF PROSTATE-CANCER- A PRELIMINARY-REPORT

      Urology
    57. WU HC; HSIEH JT; GLEAVE ME; BROWN NM; PATHAK S; CHUNG LWK
      DERIVATION OF ANDROGEN-INDEPENDENT HUMAN LNCAP PROSTATIC-CANCER CELL SUBLINES - ROLE OF BONE STROMAL CELLS

      International journal of cancer
    58. GLEAVE ME; HSIEH JT; WU HC; HONG SJ; ZHAU HE; GUTHRIE PD; CHUNG LWK
      EPIDERMAL GROWTH-FACTOR RECEPTOR-MEDIATED AUTOCRINE AND PARACRINE STIMULATION OF HUMAN TRANSITIONAL-CELL CARCINOMA

      Cancer research
    59. HSIEH JT; WU HC; GLEAVE ME; VONESCHENBACH AC; CHUNG LWK
      AUTOCRINE REGULATION OF PROSTATE-SPECIFIC ANTIGEN GENE-EXPRESSION IN A HUMAN PROSTATIC-CANCER (LNCAP) SUBLINE

      Cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/10/20 alle ore 02:31:27